Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: DNA Damage Clear all
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
DNA Damage, Other Complications Associated With Artificial Fertilization
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced May 22, 2026, 3:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
DNA Damage, Psychological Stress
Interventions
Propranolol, Placebo oral capsule, Acute stress task, No stress task
Drug · Behavioral
Lead sponsor
Dana Bovbjerg
Other
Eligibility
20 Years to 59 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced May 22, 2026, 3:37 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis
Interventions
Group 1 or Orencia treated group, Group 2 (DMARDS treated group)
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced May 22, 2026, 3:37 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 3:37 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced May 22, 2026, 3:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Family Member
Interventions
Everycell™, Placebo
Dietary Supplement · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced May 22, 2026, 3:37 AM EDT
Withdrawn Early Phase 1 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, DNA Damage Repair Deficiency
Interventions
Cyclosporin A
Drug
Lead sponsor
Virginia G. Kaklamani
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 22, 2026, 3:37 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Oxidative Stress
Interventions
6 mg xanthohumol per day, 12 mg xanthohumol per day, 24 mg xanthohumol per day, Placebo
Drug
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
glutamic acid, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced May 22, 2026, 3:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced May 22, 2026, 3:37 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced May 22, 2026, 3:37 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Smoking
Interventions
standard health information, standard health information plus info. on DNA damage, Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced May 22, 2026, 3:37 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions
Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Lymphomas
Interventions
ABT-888, Topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 3:37 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Davis, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced May 22, 2026, 3:37 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Diet
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced May 22, 2026, 3:37 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced May 22, 2026, 3:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 3:37 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced May 22, 2026, 3:37 AM EDT